Tackling the Next Generation of Resistance in EGFR-Mutant Lung Cancer

被引：3
|
作者：
Piotrowska, Zofia [1 ]
Sequist, Lecia V. [1 ]
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 03期
关键词：
ACQUIRED-RESISTANCE; INHIBITOR; HETEROGENEITY; MECHANISMS; AZD9291; MUTATIONS; THERAPY; GENE; BRAF;
D O I：
10.1016/j.jtho.2017.01.018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：419 / 421
页数：3
相关论文
共 50 条
  • [21] Genotype-Fitness Maps of EGFR-Mutant Lung Adenocarcinoma Chart the Evolutionary Landscape of Resistance for Combination Therapy Optimization
    Bolan, Patrick O.
    Zviran, Asaf
    Brenan, Lisa
    Schiffman, Joshua S.
    Dusaj, Neville
    Goodale, Amy
    Piccioni, Federica
    Johannessen, Cory M.
    Landau, Dan A.
    CELL SYSTEMS, 2020, 10 (01) : 52 - +
  • [22] Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance
    Yu, Helena A.
    Suzawa, Ken
    Jordan, Emmet
    Zehir, Ahmet
    Ni, Ai
    Kim, Ryan
    Kris, Mark G.
    Hellmann, Matthew D.
    Li, Bob T.
    Somwar, Romel
    Solit, David B.
    Berger, Michael F.
    Arcila, Maria
    Riely, Gregory J.
    Ladanyi, Marc
    CLINICAL CANCER RESEARCH, 2018, 24 (13) : 3108 - 3118
  • [23] The next tier of EGFR resistance mutations in lung cancer
    Tumbrink, Hannah L.
    Heimsoeth, Alena
    Sos, Martin L.
    ONCOGENE, 2021, 40 (01) : 1 - 11
  • [24] Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer
    Zhu, Viola W.
    Klempner, Samuel J.
    Ou, Sai-Hong Ignatius
    TRENDS IN CANCER, 2019, 5 (11): : 677 - 692
  • [25] Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer
    Cai, Xueting
    Miao, Jing
    Sun, Rongwei
    Wang, Sainan
    Molina-Vila, Miguel Angel
    Chaib, Imane
    Rosell, Rafael
    Cao, Peng
    PHARMACOLOGICAL RESEARCH, 2021, 170
  • [26] EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
    Otsuka, Kyoko
    Hata, Akito
    Takeshita, Jumpei
    Okuda, Chiyuki
    Kaji, Reiko
    Masago, Katsuhiro
    Fujita, Shiro
    Katakami, Nobuyuki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (04) : 835 - 841
  • [27] A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR-Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib
    Yu, Helena A.
    Perez, Leslie
    Chang, Qing
    Gao, Sizhi P.
    Kris, Mark G.
    Riely, Gregory J.
    Bromberg, Jacqueline
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : 102 - 109
  • [28] Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer Implications for Oncogene-Driven Lung Cancer
    Gavralidis, Alexander
    Gainor, Justin F.
    CANCER JOURNAL, 2020, 26 (06) : 517 - 524
  • [29] Macrophage renewal modes affect acquired resistance to gefitinib in EGFR-mutant lung cancer PC-9 cells
    Zhao, Baoxia
    Zhang, Yan
    Lu, Shen
    Li, Mei
    ONCOLOGY REPORTS, 2023, 49 (02)
  • [30] Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer
    de Miguel, Fernando J.
    Gentile, Claudia
    Feng, William W.
    Silva, Shannon J.
    Sankar, Akshay
    Exposito, Francisco
    Feng, Wesley L.
    Melnick, Mary Ann
    Robles-Oteiza, Camila
    Hinkley, Madeline M.
    Tsai, Jeanelle A.
    Hartley, Antja-Voy
    Wei, Jin
    Wurtz, Anna
    Li, Fangyong
    Toki, Maria I.
    Rimm, David L.
    Homer, Robert
    Wilen, Craig B.
    Xiao, Andrew Z.
    Qi, Jun
    Yan, Qin
    Nguyen, Don X.
    Janne, Pasi A.
    Kadoch, Cigall
    Politi, Katerina A.
    CANCER CELL, 2023, 41 (08) : 1516 - +
12345